Table 2 Subgroup analysis of clinical outcomes by clinical and demographic characteristics
Characteristics | N (%) | ||
|---|---|---|---|
Cure/improvement | Death/death related to COVID-19 | No improvement | |
Age group (years) | |||
12–20 | 4 (80.00) | 0 (0.00) | 1 (20.00) |
20–40 | 278 (91.45) #* | 11 (3.62) ##** | 15 (4.93) ###*** |
40–60 | 826 (85.33) $ | 52 (5.37) $$ | 90 (9.30) $$$ |
≥ 60 | 549 (78.99) | 70 (10.07) | 75 (10.79) |
Gender | |||
Male | 1,206 (83.29) @ | 108 (7.46) @ | 134 (9.25) @ |
Female | 451 (86.07) | 26 (4.96) | 47 (8.97) |
Diabetes | |||
Yes | 489 (78.36) | 62 (9.93) | 72 (11.54) |
No | 1,136 (85.52) | 71 (5.41) | 106 (8.07) |
Hypertension | |||
Yes | 377 (87.06) | 23 (5.32) | 33 (7.62) |
No | 1,248 (82.98) | 110 (7.31) | 145 (9.64) |
Other cardiac conditions | |||
Yes | 105 (81.40) | 19 (14.73) | 5 (3.88) |
No | 1,520 (84.07) | 114 (6.31) | 173 (9.57) |
Lung disease | |||
Yes | 72 (77.42) | 10 (10.75) | 11 (11.83) |
No | 1553 (84.22) | 123 (6.67) | 167 (9.06) |
Received oxygen support | |||
Yes | 1608 (83.62) | 134 (6.97) | 181 (9.41) |
No | 37 (100.00) | 0 (0.00) | 0 (0.00) |
SLFO | 1107 (93.97) | 26 (2.21) | 45 (3.82) |
HFO | 332 (80.58) §§ | 24 (5.82) § | 56 (13.59) §§ |
NIV | 146 (57.71) §§ | 48 (18.97) §§ | 59 (23.32) §§ |
MV | 23 (28.75) §§ | 36 (45.00) §§ | 21 (26.25) §§ |
Remdesivir treatment time | |||
< 5 days | 312 (75.5) §§§ | 59 (14.3) §§§ | 42 (10.2) |
5 days | 1095 (87.0) | 56 (4.4) | 108 (8.6) |
6–10 days | 183 (85.9)@@@ | 14(6.6)@@@ | 16 (7.5) |
> 10 days | 15 (100) | 0 | 0 |
Received steroids | 383 (79.95) @@ | 40 (8.35) @@ | 56 (11.69) @@ |
Received antibiotics | 456 (79.31) | 52 (9.05) | 67 (11.65) |
Received anticoagulants | 253 (81.35) | 19 (6.11) | 39 (12.54) |